Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CRH upbeat after revenues, profits jump

(Sharecast News) - Irish building materials group CRH forecast another strong performance in 2025, after it posted a jump in full-year earnings. The New York-listed firm, which posted annual results after markets closed on Wednesday, said total revenues rose 2% in 2024, to $35.6bn, while net income jumped 15% to $3.5bn.

Adjusted earnings before interest, tax, depreciation and amortisation rose 12% to $6.9bn.

Jim Mintern, who was appointed chief executive at the end of last year, said: "2024 was a strong year for CRH, driven by our customer-connected solutions strategy and leading positions of scale in attractive, higher growth markets.

"The outlook for our business remains positive, underpinned by favourable demand and positive pricing momentum, leaving us well positioned for another year of growth and value-creation ahead."

Looking to the current year, CRH - which makes around 75% of its profits in North America - said it was well placed to benefit from "significant" public investment in critical infrastructure as well as increased re-industrialisation activity outside of the residential market.

As a result, it expects 2025 net income to come in between $3.7bn and $4.1bn, and adjusted EBITDA of between $7.3bn and $7.7bn.

As at 0915 GMT, the stock was down 1% in pre-market trading on Wall Street, and 1% lower at 8,016p in London.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.